SWM
BPMC

SeaCrest Wealth Management’s Blueprint Medicines BPMC Stock Holding History

SeaCrest Wealth Management’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-91
Closed -$6K – 2259
2018
Q2 		$6K Hold
91
– – ﹤0.01% 1753
2018
Q1 		$8K Hold
91
– – ﹤0.01% 1649
2017
Q4 		$7K Buy
+91
New +$6.4K ﹤0.01% 1700

Other funds holding BPMC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
HIM
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return

SeaCrest Wealth Management's BPMC Position: Q3 2018 in Review

SeaCrest Wealth Management sold out of Blueprint Medicines (BPMC) in Q3 2018, closing a stake of 91 shares — an estimated $6K sold.

SeaCrest Wealth Management first reported a position in BPMC in Q4 2017 and held it in 3 quarters. The position peaked at $8K in Q1 2018. 188 funds tracked by Wall St. Rank hold BPMC as of Q3 2018.

  • SeaCrest Wealth Management reported no remaining Blueprint Medicines position as of Q3 2018 after selling out during the quarter.
  • SeaCrest Wealth Management sold 91 Blueprint Medicines shares in Q3 2018, an estimated $6K.
  • SeaCrest Wealth Management first reported a position in Blueprint Medicines in Q4 2017 and held it in 3 quarters.
  • SeaCrest Wealth Management's Blueprint Medicines position peaked at $8K in Q1 2018.
  • 188 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2018.

Based on SeaCrest Wealth Management's 13F filing for Q3 2018, filed 14 Nov 2018.